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Abstract 
Canine transmissible venereal tumor (CTVT) is a parasitic cancer clone that has 
propagated for thousands of years via sexual transfer of malignant cells. Little is understood 
about the mechanisms that converted an ancient tumor into the world’s oldest known 
continuously propagating somatic cell lineage. We created the largest existing catalog of canine 
genome-wide variation and compared it against two CTVT genome sequences, thereby 
separating alleles derived from the founder’s genome from somatic mutations that must drive 
clonal transmissibility. We show that CTVT has undergone continuous adaptation to its 
transmissible allograft niche, with overlapping mutations at every step of immunosurveillance, 
particularly self-antigen presentation and apoptosis. We also identified chronologically early 
somatic mutations in oncogenesis- and immune-related genes that may represent key initiators of 
clonal transmissibility. Thus, we provide the first insights into the specific genomic aberrations 
that underlie CTVT’s dogged perseverance in canids around the world. 
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Introduction 
Clonally transmissible tumors arise in a single founder case and spread to other members 
of the same species via allogeneic communication of cancer cells. This phenomenon is known to 
have evolved independently only twice in mammals: in Tasmanian devils and canines, lineages 
that diverged over 180 million years ago (Meredith et al. 2011). Canine transmissible venereal 
tumor (CTVT) is a sexually transmitted tumor clone that has continuously proliferated for 
thousands of years, and is now endemic in the canine populations of at least 90 countries 
(Strakova and Murchison 2014). CTVT typically avoids rejection by the host immune system for 
months, but is subsequently identified and eliminated in immunocompetent individuals (Yang 
1988). Since all CTVT cancers are derived from a single founder tumor, they show strong 
genetic identity with one another, but are markedly distinct from their transient host (Katzir et al. 
1987; Murgia et al. 2006; Murchison et al. 2014). Leveraging this key principle of clonal 
transmissibility, a recent study characterized genomic elements shared by and unique to two 
CTVT tumors (Murchison et al. 2014). However, the obvious unavailability of germline DNA 
from the long-deceased founder animal prevented accurate discrimination between somatically 
acquired mutations and the genetic variation (the CTVT founder canid’s inherited alleles) that 
was present in the founder canid prior to oncogenesis of the initial tumor. Consequently, only a 
few candidate somatic drivers of CTVT were identified, and the genomic mechanisms that allow 
the tumor to thrive in diverse canine hosts remained largely undefined. 
 To better address these questions, we hypothesized that the founder’s inherited alleles 
could be identified by comparing the CTVT genome against inherited polymorphisms found in 
whole genome sequences from a diverse cross section of wild and domesticated modern canids. 
Furthermore, variants not found in other canids are likely dramatically enriched for somatic 
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mutations, and a subset of these must represent key mediators of CTVT’s remarkable behavior. 
Here, we constructed the most comprehensive existing catalog of canine genomic variation, 
facilitating the first accurate dissection of the genetics underpinning CTVT biology by 
examining the somatic mutation landscape. 
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Results  
A previous report on two CTVT tumors leveraged canine dbSNP to identify polymorphic 
alleles inherited by the CTVT founder (Murchison et al. 2014); however, canine dbSNP only 
accounts for an average of 32.65% of the germline SNVs found in whole genome sequencing 
(WGS) of diverse canids (Fig. 1A). Therefore, published canine polymorphisms are not 
sufficient for identification of the CTVT founder’s inherited alleles. To overcome this limitation, 
we generated high-coverage WGS (mean 37.9X) for 51 dogs from closed breeding populations, 
and jointly genotyped these with 135 publicly available canine genomes, thereby creating the 
largest current catalog of genome-wide canine variation representing 186 diverse canids (Table 
S1). Since we also wanted to exclude recurrent systematic sequencing or genotyping errors from 
downstream analysis of somatic mutations, variant positions that were identified by GATK 
HaplotypeCaller, but did not pass variant quality score recalibration were retained for use as a 
systematic error filter. Together with canine dbSNP (Sherry 2001) and a recently published 
variation survey (Axelsson et al. 2013), our canine Variation and Systematic Error Catalog 
(VSEC) consisted of 28.01 million single nucleotide variants (SNVs), 12.62 million indels, and 
31,613 structural variants (SVs) (Databases S1-3). Whereas canine dbSNP contains only SNVs 
and includes less than one-third of the variants found in the average canid whole genome 
sequence, a mean of 99.55% of SNVs, 99.57% of indels, and 95.63% of SVs from any single 
canid were present in at least one other individual in our newly developed, WGS-derived VSEC 
catalog (Fig. 1B-D).  
Due to the unique natural history of CTVT, variants shared by two or more tumors were 
present in the most recent common ancestor tumor. To leverage this identity by descent 
phenomenon, we compared high quality variants shared by the two published CTVT sequences 
 Cold Spring Harbor Laboratory Press on August 13, 2015 - Published by genome.cshlp.orgDownloaded from 
  6
(Murchison et al. 2014) against the VSEC catalog (Fig. 1E). CTVT variants contained in the 
VSEC catalog were presumed to be the founder’s inherited alleles, while novel variants were 
classified as candidate somatic mutations (Kumar et al. 2011) (see Table S2 for high- and 
moderate-impact candidate somatic mutations). By these criteria, 75.6% of SNVs, 92.1% of 
indels, and 17.6% of SVs originated in the founder’s germline, while the remainder were 
somatically acquired (Table 1 and S3). These candidate somatic variants were dramatically 
different from germline alleles, but consistent with human tumor mutations for metrics including 
transition-transversion ratio (Ti/Tv), nonsynonymous-synonymous ratio (N/S), and conservation 
at mutated positions (phastCons) (Fig 2A-C). We also investigated substitution signatures within 
their trinucleotide sequence context. The putative founder-inherited alleles were 
indistinguishable from germline variants in modern canids, with C>T and T>C substitutions 
occurring somewhat more frequently than other variants (Fig. 2D-E). The candidate somatic 
mutations had a strikingly different signature that did not include overrepresentation of T>C 
variants, but instead showed a dramatic enrichment for TCC>TTC and CCC>CTC substitutions. 
As previously observed (Murchison et al. 2014), we found that dinucleotide substitutions were 
dominated by CC>TT and GG>AA substitutions (Fig. S1). Both the trinucleotide and 
dinucleotide substitution patterns observed in CTVT also occur in human melanomas, and have 
been linked to UV radiation exposure (Alexandrov et al. 2013).  
Examination of gene-specific N/S highlighted 16 genes with strong enrichment for 
somatic nonsynonymous substations (Z > 3.0) when compared to high coverage individuals 
within the VSEC (Table S4).  These genes are involved in cell adhesion (CHL1), extracellular 
cohesion (COL11A1), cytoskeletal structure and function (CDC42BPA, MACF1), cell membrane 
structure (HSPG2), caspase and apoptotic signal transduction (CARD6, MADD), and chromatin 
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organization / histone modification (NIPBL, ASH1L, KMT2A), as well as genes expressed almost 
exclusively in specific tissues such as testis (RNF17) or muscle (UCP3).  Each gene contained at 
least one mutation with the most severe SIFT (Ng and Henikoff 2001) tolerance score (< 0.05), 
suggesting the imposition of a significant molecular burden during tumor evolution. 
Previous analysis of these tumors identified over three million candidate somatic SNVs 
(Murchison et al. 2014), which even after adjustment for missed germline variants overestimated 
the tumor-specific changes due to misclassification of the founder’s inherited alleles as somatic 
changes. Filtering with the VSEC catalog in place of dbSNP, we found that CTVT tumors shared 
910,376 high-confidence somatic substitutions, an order of magnitude more than even the most 
mutated human cancers, but 66% fewer than the previous analysis of these tumors (Alexandrov 
et al. 2013; Murchison et al. 2014). Functional annotation highlighted 586 high-confidence 
truncating SNVs, 723 frameshift indels, and 2,920 SVs that span at least one exon (Table 1), 
which together affect 2,247 genes (Table S2). Due to this very large number of likely damaging 
somatic mutations, we used Gene Set Enrichment Analysis (Subramanian et al. 2005) to identify 
pathways with the greatest enrichment for high-impact somatic disruptions. For genes affected 
by somatic truncating SNVs, frameshift indels, or exon-spanning SVs, the most enriched 
pathway was the “Reactome immune system” with a reported p-value of 2.27x10-25 (Table S5). 
Looking more closely at immune-related pathways, we observed candidate somatic 
mutations spanning all aspects of somatic cell participation in immunosurveillance (Table S6). 
This included candidates in the self-antigen presentation pathway such as ERAP1, which trims 
peptides for binding in antigen presentation molecules (York et al. 2002; Saric et al. 2002), and 
each component of the transporter associated with antigen processing (TAP1, TAP2, TAPBP), 
which facilitates peptide localization and loading into self-antigen presentation molecules (Table 
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S2) (Spies et al. 1992). Candidate somatic mutations were also enriched among genes involved 
in the initiation and execution of apoptosis (Fig. 3A) and maintenance of genome integrity 
(Table S2). 
We also used the CTVT and canid genomes to investigate the somatic genomic 
architecture of CTVT at base-pair resolution. CTVT tumors worldwide share a highly 
rearranged, aneuploid genome with 57-59 chromosomes, compared to 78 in normal canids, 
although copy number analysis and chromosome painting indicate that much of the genome 
content is preserved (Murchison et al. 2014; Thomas et al. 2009). Our base pair-resolution 
analyses uncovered the specific manifestation of these structural rearrangements, including 7,338 
deletions, duplications, inversions, and translocations that underlie the unusual shared karyotype 
of CTVT tumors (Fig. 3B). In addition, we also found evidence for at least 247 potential gene 
fusions that may contribute to loss-of-function and aberrant gene action (Table S7).  
We leveraged the unbalanced nature of somatic loss-of-heterozygosity (LOH) events to 
establish a putative chronology for a subset of the somatic mutations. The regional homozygosity 
fraction (HF,   
   
    
) for both somatic mutations and founder-inherited 
alleles is 1.0 after such a LOH event. Since the germline genetic variation from the lost copy of 
the chromosome cannot be replaced, the HF of founder-inherited alleles must remain at ~1.0, 
irrespective of subsequent tumor evolution. In contrast, somatic HF in such regions declines over 
time due to accrual of additional, heterozygous post-LOH somatic mutations. This phenomenon 
allows the establishment of chronology for somatic mutations in LOH-affected regions – 
homozygous somatic mutations likely originated prior to the LOH event, whereas heterozygous 
mutations arose afterwards. Furthermore, since somatic mutation HF declines as a function of the 
mutation rate and elapsed time, this metric allows estimation of the relative age of different LOH 
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events. On this basis, we defined regions that underwent copy-neutral LOH in the distant past by 
identifying 1-Mb regions with >85% homozygosity among alleles inherited by the founder, but 
<50% homozygosity among somatic mutations (Fig. 3 C-D, Fig. S2). The full list such 
potentially ancient somatic mutations can be found in Tables S8 and S9.  
Leveraging our diverse sampling of existing canine variation to accurately discriminate 
candidate somatic mutations from putative founder-inherited variation enabled us to show the 
CTVT founder’s relationship to contemporary breeds, as well as to pinpoint the geographic 
origin of this ancient canine. To place the founder’s inferred, reconstructed genome in the 
context of contemporary variation, we constructed a maximum likelihood phylogeny using 1.3 
million informative founder-inherited alleles. The observed high bootstrap support confidently 
places the founder as a post-domestication canid, and phylogenetic concordance was highest 
with contemporary Arctic spitz breeds (Fig. 4A and S3), which agrees with the earlier SNP-chip 
based analysis of these same tumors (Murchison et al. 2014). To dissect this result, we used 
principal components analysis to explicitly model ancestry differences between among Arctic 
spitz breed dogs the CTVT genotypes. For principal components 1 and 2, the CTVT tumors 
clustered nearest the Alaskan malamutes (Fig. 4B). 
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Discussion 
We created the largest existing catalog of canine genetic variation and compared it to two 
CTVT tumors, thereby isolating CTVT’s somatic changes from the genetic variation that was 
present in the founder canid. As demonstrated by our comparison of one sequenced canid against 
all others, our VSEC catalog encompasses the vast majority of modern canine genetic variation, 
and should therefore contain most CTVT founder-inherited alleles (Fig. 1B-D). Independent of 
this study, the VSEC catalog will be integral to the identification of breed-specific and shared 
genomic variation between breeds, the investigation of other canine cancers, as well as rare 
diseases. It represents the most exhaustive breadth of canine genomic sampling, combined with 
the deepest sequencing for individuals within closed-breeding populations of dogs. 
Despite our unrivaled survey of canine genomic variation, we note that our approach 
misclassifies founder-inherited alleles that are not represented in our panel of modern canids, 
instead defining these as somatic changes acquired since tumor inception. Since the misclassified 
alleles amount to private variation in the founder, we estimated the magnitude of this effect using 
the observed level of private variation among the 186 sequenced canids. The globally-
ascertained wolves in our WGS panel harbored the most private variation, presumably reflecting 
the genetic bottleneck of domestication. If the CTVT founder had a high level of private 
variation equal to modern wolves, we projected that the true number of CTVT somatic variants 
would be approximately 3.7% lower than the number of candidate somatic mutations (Fig. S4). It 
remains possible that the ancient founder canid had a level of private variation that vastly 
outstripped the private genetic diversity of modern wolves. However, this scenario is unlikely 
because the Ti/Tv, N/S, and phastCons profiles of the candidate somatic mutations are divergent 
from the values observed during the course of evolution in other organisms (Yang and Nielsen 
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1998; Yang and Yoder 1999), as well as from the germline variants of all 186 sequenced canids 
(Fig. 2A-C). Instead, the candidate somatic mutations mirror trends observed for somatic 
mutations in human tumors. Furthermore, the somatic mutations exhibited a completely different 
substitution profile from germline alleles, including a much lower T>C substitution rate than the 
inherited variants, accounting for 14.6 % and 33.5%, respectively (Fig. 2D-F). Somatic 
mutations also demonstrated a predilection for C>T substitutions and CC>TT dinucleotide 
substitutions (Fig. 2D-F, S1), a signature of UV exposure in human melanomas (Murchison et al. 
2014; Alexandrov et al. 2013). Together, the low rate of private variation in even the most 
divergent canids, significant differences in mutation metrics, and recapitulation of trends found 
in human tumors, but not natural evolution suggest that although residual founder-inherited 
alleles are present, they are uncommon among the candidate somatic mutations. Based on these 
lines of evidence, paired with fact that the protracted natural history of CTVT implies an 
elevated somatic mutation burden, we inferred that variants not found in other canids are highly 
enriched for somatic mutations. Accordingly, these variants were evaluated for prospective 
contributions to clonal transmissibility. 
Our analysis revealed candidate somatic mutations disrupting every step of the adaptive 
immune safeguards that typically detect and destroy allografted cells (Fig. 3A and Table S6). 
Normally, T-cells scrutinize cytosolic peptide fragments presented in the context of self-antigen 
presentation molecules. CTVT mutations block generation of antigenic peptides, prevent their 
transport into the endoplasmic reticulum, and inhibit their loading into self-antigen presentation 
molecules. In addition to dozens of somatic mutations affecting ubiquitination and protein 
cleavage, CTVT has a deleterious missense substitution in ERAP1, which trims peptide 
fragments for ideal fit in antigen presentation molecules (York et al. 2002; Saric et al. 2002). 
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Truncating or predicted deleterious mutation candidates affect all three components of the 
transporter associated with antigen processing (TAP1, TAP2, TAPBP), which imports cytosolic 
protein fragments into the endoplasmic reticulum and facilitates antigen presentation molecule 
loading (Table S2) (Spies et al. 1992). This collection of mutations limits antigenic peptide 
fragment availability (Van Kaer et al. 1992; York et al. 2002; Saric et al. 2002) and together, 
these overlapping somatic mutations likely underlie the observation that CTVT has low surface 
MHC class I (Murgia et al. 2006), and prevent host T-cells from initiating an immune response. 
In addition to preventing recognition by the host, CTVT also likely disrupts immune 
rejection via somatic mutations in numerous initiators and executors of apoptosis (Fig. 3A). 
Among other mutations (Table S6), both tumors harbor predicted deleterious mutations in 
CFLAR, IGF2R, DAPK1, DAPK2, FADD, TNFRSF1A, TRADD and TRAF2, genes that inhibit 
the ability of T and NK cells to induce apoptosis via either cytolytic granules or death receptors. 
For example, IGF2R can facilitate the entry of granzyme into cells, while FADD recruits and 
cleaves CASP8 upon activation of the FAS or TNF receptors (Motyka et al. 2000; Imai et al. 
1999). Apoptotic pathways converge at caspase 3, an executioner protease that activates DNA- 
and mitochondria-damaging death substrates (Darmon et al. 1995; Enari et al. 1996). In CTVT, a 
homozygous Chromosome 16 to 9 translocation in the second intron of CASP3 dislodges the 
gene’s transcription start site and 5'-UTR, likely preventing expression of this key effector of 
apoptosis. The tumor also has mutations in many other genes that modulate the balance of pro- 
and anti-apoptotic signaling (Fig. 3A). 
Broadly, we conclude that CTVT avoids immune-mediated destruction via a combination 
of mechanisms employed by other malignancies. For example, allografted murine tumors with 
low self-antigen presentation due to TAP1 suppression do not elicit rejection in 
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immunocompetent mice (Shankaran et al. 2001), and the same strategy is deployed via 
epigenetic means in Tasmanian devil facial tumor (Siddle et al. 2013). In addition, most cancers 
disrupt the balance between survival and apoptotic signaling. While many tumors employ a small 
subset of the immune evasion repertoire apparently at work in CTVT, this tumor is remarkable 
for the redundant, comprehensive combination of mutations that continues to facilitate its 
unparalleled horizontal transmissibility. These functionally overlapping mutations are likely the 
manifestation of the thousands of years and unique evolutionary pressures that have molded this 
transmissible allograft. 
Through careful analysis of the numerous read mapping inconsistencies between CTVT 
and the CanFam3 genome within the context of contemporary variation, our work specifically 
identifies the location and nature of genome-wide somatic structural aberrations (Table S2). 
Somatic mutations in DNA repair and genome stability genes likely contributed to the observed 
genomic disarray in CTVT, as we found truncating or predicted damaging changes in ATM, 
BRCA1, BRCA2, MRE11A, MLH1, PMS1, RAD21, and TP53 (Table S2). This instability likely 
leads to the previously reported copy-neutral somatic loss LOH events (Thomas et al. 2009; 
Murchison et al. 2014), which result from single-copy loss of a chromosome segment and 
concomitant duplication of the other copy. This phenomenon initially causes all inherited and 
acquired variants in the affected region to become homozygous. The unbalanced nature of some 
structural rearrangements enabled us to identify some early somatic mutations in genes essential 
to proper cellular function such as TP53, CASP3, TAP2, and CDKN2A/B, which have well-
described roles in oncogenesis and immune evasion (Tables S8 and S9). While the homozygous 
deletion of CDKN2A/B was one of the four putative somatic drivers of CTVT identified in 
previous analysis of these tumors (Murchison et al. 2014) our ability to specify additional 
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mutations (Tables S8 and S9), as well as place the timing of these changes during early tumor 
evolution, underscores the major role that these additional genetic alterations may have played in 
oncogenesis. These and other early mutations must have enabled the founder tumor to rapidly 
proliferate and escape detection by new hosts, initiating the transition from ancient tumor to 
infectious allograft. 
In light of our discovery that CTVT has multiple somatic mutations in DNA repair genes 
including MLH1, a mismatch repair mediator associated with somatic hypermutation (Zhao et al. 
2014), modeling CTVT’s mutation rate is problematic using only two genomes. Nevertheless, 
our significantly reduced number of putative somatic SNVs, paired with an increased mutation 
rate commensurate with multiple DNA repair defects and UV radiation exposure, implies a much 
more recent origin for CTVT than the previous estimate of 11,000 years (Murchison et al. 2014).  
Even given CTVT’s origin within a more recent timeframe, this allograft represents a 
unique organism that defies current taxonomic classification. Originating as a canine cell, the 
ameiotic acquisition of mutations via Muller’s ratchet (Muller 1964) promoted accumulation of 
some mutations deleterious to normal mammalian cells, and others advantageous to self-
propagation via inter-organismal transmissibility. In the process, the tumor was transformed 
from a multicellular cancer to a loosely organized unicellular colony. As an infectious allograft, 
it has adopted strategies similar to intercellular obligate parasites (Wijayawardena et al. 2013), 
even subsuming mitochondria from its host (Rebbeck et al. 2011). In spite of these many 
mechanisms at work, our phylogenetic inference firmly placed the founder canine after the 
emergence of Canis lupus familiaris (Fig. 4A and S3), and further investigation pointed to the 
Alaskan malamute as the closest modern canid to the CTVT founder (Fig. 4B). 
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Though CTVT’s unusual life history complicates dissection of its genome, our survey of 
variation in modern canids facilitated accurate enrichment of somatic mutations. Our 
comprehensive catalog can be readily utilized to investigate the genomic characteristics 
underlying other manifestations of canine cancer, as well as rare disease phenotypes. By 
leveraging it against two CTVT tumor genomes, we reveal critical and early somatic mutations 
that likely contributed to the rise of clonal transmissibility. Furthermore, key survival strategies 
manifest as redundant, high-impact somatic mutations spanning immunosurveillance pathways. 
These observations exemplify the myriad adaptations that transformed a single canine tumor into 
a parasitic, globally distributed, clonally transmissible cell lineage. After millennia of molding in 
this crucible of selection, CTVT has evolved into an unrivaled laboratory for studying the tumor-
host arms race, as well as immunomodulating therapeutics that unbalance this struggle. 
 
 
Methods 
Canine genome sequencing and data aggregation 
Whole genome sequences were generated for 51 individuals belonging to closed breed 
populations using the Illumina TruSeq DNA PCR-Free Protocol (Cat# FC-121-3001). Libraries 
were constructed with 300-500bp fragments and sequenced on the Illumina HiSeq2000 platform 
using 100bp paired-end parameters. To fully explore the documented variation in canines, 
sequences for all canine genomes available at the onset of this study that were sequenced on a 
contemporary Illumina platform were also obtained via BioProject accessions from the Sequence 
Read Archive or the European Nucleotide Archive (Table S1). 
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SNV and indel identification and filtering 
To construct the genome for each individual, paired-end sequences were aligned to the 
CanFam3 reference genome using the BWA 0.7.10 MEM algorithm (Li and Durbin 2009), and 
sorted with SAMtools 0.1.19 (Li et al. 2009). Putative PCR duplicate reads were annotated with 
PicardTools 1.119 (github.com/broadinstitute/picard) and not used for subsequent variant or 
copy number detection. Local realignment around documented and novel insertion-deletion 
events was performed using published indel data (Axelsson et al. 2013), and base quality 
recalibration using dbSNP and positions from the Illumina Canine HD chip data as training sets 
with GATK 3.2-2 (DePristo et al. 2011). Putative SNVs were identified in each sample and 
genotyped across all 188 samples simultaneously using GATK HaplotypeCaller in GVCF mode 
(Van der Auwera et al. 2013). Variant quality score recalibration (VQSR) was executed 
separately for SNVs and indels using GATK best practices recommendations with the same 
training sets as implemented in the indel realignment and base quality recalibration steps. 28.01 
million raw SNV positions and 12.62 million raw indel positions were identified, and all that 
were not private to the CTVT genome were retained for use in the variation and systematic error 
catalog (Databases S1-2). For downstream variant analysis of individual genomes, we retained 
only those that passed the 99.0 tranche for VQSR, with VQSlod <-0.0594 for SNVs and VQSlod 
<-9.7328 for indels. The VQSR status for SNV and indel positions is indicated in Databases S1-
2.  
We then determined how many variants from one canid were found in at least one other 
individual in the panel. For each canid, we used VCFtools (Danecek et al. 2011) to extract 
variants that passed VQSR and had a genotype quality >20, and these variants were then filtered 
against a list of positions with a variant of the same type of any quality in any other canid. We 
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allowed indel start positions to differ by +/-1bp to account for the decreased precision of indel 
localization. After establishing that the vast majority of variants present in one canid can be 
found in at least one other in our diverse panel (Fig. 1B-D), we applied the same approach to the 
two CTVT tumors. 
The genome sequence of CTVT represents a complex mixture of entities: contamination 
from the canine host, systematic errors, alleles inherited by the founder, lineage-specific somatic 
mutations, and earlier somatic mutations that must be the essential drivers of clonal 
transmissibility. Since CTVT is most remarkable for its persistence as a transmissible somatic 
cell lineage, our variant filtering approach was designed to enrich for somatic mutations shared 
by both tumors. Accordingly, we aggressively sought to remove both systematic errors and 
polymorphic alleles inherited by the founder. Among putative somatic mutations, we also 
excluded lineage-specific variants, and those with lower quality in one or both tumors. To 
accomplish these goals, we used the quality and depth thresholds described above to identify 
high-confidence variants shared by both tumors. These variants were filtered against the type-
specific catalogs of positions with variants of any quality in any of the 186 modern canids 
(Databases S1-3). Shared CTVT variants that are in our VASC database were likely inherited by 
the founder, though this set also contains host contamination and systematic false positives. 
Novel variants were evaluated as somatic mutations, though these also contain variants inherited 
by the ancient founder, but not present in our panel of modern canids. Putative somatic mutations 
within repetitive elements were also removed 
(http://hgdownload.cse.ucsc.edu/goldenPath/canFam3/database/rmsk.txt.gz). Remaining somatic 
mutations were annotated with the Variant Effect Predictor (McLaren et al. 2010) and evaluated 
for potential contributions to clonal transmissibility. 
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Genome-wide and gene-specific substitution ratios 
 Utilizing the variant effect prediction annotations for missense and nonsense 
(nonsynonymous, N), as well as synonymous (S) mutations, genome-wide and gene-specific 
totals for N and S were tallied. The N/S ratio was calculated for each protein-coding gene using 
the Ensembl v79 gene models (Flicek et al. 2014) for both putative somatic and founder-
inherited variants as well as a panel of 20 high coverage canids (Table S4) (Nei and Gojobori 
1986). Average values across the canid panel were compared to those of putative somatic 
variants from CTVT to highlight genes with enrichment for nonsynonymous changes as well as 
severely deleterious SIFT (Ng and Henikoff 2001) scores (< 0.05), indicating untolerated and 
repeated loss of normal function (Ostrow et al. 2014). 
 
Structural variant identification and filtering 
DELLY v0.5.5 was used to detect deletions (DEL), tandem duplications (DUP), 
inversions (INV) and translocations (TRA) in CTVT tumors and the normal canid genomes 
(Rausch et al. 2012). Raw DELLY calls were filtered for size <1kb or/and when either SV 
breakpoint fell within 100kb from the start or end of the canine chromosome. Candidate SVs 
were merged into a single event when both breakpoints were +/- 200 bp for INV, DEL, DUP and 
+/- 500 bp for TRA. SVs were also filtered if SR<1 and PE<5 or PE<1 and SR<5. We identified 
SVs found in both CTVT tumors, and then filtered these against all SVs present in any of the 
canid genomes. 
For somatic TRA in CTVT, we identified SVs in tumor 79T and imposed quality filters 
and then subtracted against all variants present in any of the canid genomes. Since we sought 
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TRA shared by both tumors, we extracted reads within 1kb of the 79T TRA breakpoints for both 
24T, merged these reads with 50 million properly mapped read pairs, and employed the 
procedures described above. 
We used the depth-based copy number algorithm CNVnator v0.3 to identify genomic 
regions with homozygous deletions or duplications in the CTVT tumor genomes (Abyzov et al. 
2011). After CNVs were called with a bin size of 400-bp, we removed low-confidence calls by 
filtering events with 1) E-value < 0.01, 2) >50% of reads with mapping quality zero, or 3) gap in 
the reference sequence constituting more than 35% of the region. We retained deletions with a 
normalized read depth (RD) ≤0.6 for the control genomes and ≤0.25 for the union of the CTVT 
tumors. For duplications, we kept those with with a normalized RD ≥1.4 for the control genomes 
and ≥2 for the union of the CTVT tumors. Finally, we filtered the union of the CTVT tumor 
CNVs against all CNVs present in any of the canid control genomes. Chromosome to 
chromosome translocation events were plotted in Circos (Krzywinski et al. 2009). 
 
Gene Set Enrichment Analysis 
 Among the somatic mutation candidates, all stop-gained, stop-lost, frameshift, and SVs 
that disrupted an exon, were evaluated with the online version of Gene Set Enrichment Analysis 
(http://www.broadinstitute.org/gsea/msigdb/annotate.jsp). Somatic mutation candidates were 
compared against the “canonical pathways” gene sets, and a stringent false discovery rate of 
0.0001 was specified. The top 100 most significantly mutated pathways for these protein-altering 
variants and disruptive SVs can be found in Table S5. The most enriched pathway was the 
“Reactome Immune System,” and this pathway was further investigated. 
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Identification of Early Somatic Mutations 
 CTVT genotypes were assigned to founder-inherited alleles and somatic mutations. All 
positions where either host canid had variant alleles were excluded to avoid conflation of host 
contamination with CTVT founder-inherited alleles. Genotype assignments were corrected for 
host contamination using variant allele fraction (VAF), defined as alternate allele depth divided 
by total depth. Based on the observed VAF distribution for founder-inherited alleles (Fig. S5), 
SNVs with VAF between 0.25 and 0.55 were called heterozygous, while variants with VAF > 
0.65 were called homozygous. Variants outside these ranges could not be reliably assigned to 
either state, and therefore were not included in this analysis.  
  Regional homozygosity fraction (HF, number of homozygous alternate variants divided 
by total variants) was calculated independently for founder-inherited alleles and somatic 
mutations in 1-Mb sliding windows with 250kb step size across the genome. LOH regions were 
defined as intervals with germline HF > 0.85, and the subset of these regions with somatic HF < 
0.50 were designated as ancient LOH events, on the basis that half of the variants arose after the 
LOH event.  Variants with depth <10 were excluded from the sliding window analysis. 
Homozygous SNVs and indels with depth >20, as well as all SVs in likely ancient LOH regions, 
were identified and evaluated. The mean depth at the remaining positions was 105.0 and 45.6 for 
CTVT 24T and CTVT 79T, respectively. 
 
Maximum Likelihood Phylogeny 
To place the germline-specific variants into an evolutionary context within our catalog of 
variation, we extracted putative founder-inherited alleles at the 1,380,310 SNV positions where 
the host dogs had no evidence for variation. We also included two wild canids, golden jackal and 
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Andean fox. Homozygotes were coded by their respective nucleotide, and heterozygotes by the 
IUPAC code for the respective 2-base combination. Calls falling below the VQSlod threshold 
were coded as unknown “N”. Positions determined to be invariant were excluded. The resulting 
multi-alignment was partitioned by chromosome and evaluated for an appropriate nucleotide 
substitution model in 10kb sub-partitions using ModelTest (Posada 2006). Each 
intrachromosomal subpartition with an identical substitution model was concatenated, and the 
final data converted to Phylip format with Perl. Using the phylogentic supercomputing resource 
CIPRES, a comprehensive maximum likelihood analysis was executed using ExaML for 10 
regular treespace searches and RAxML for 150 rapid bootstrap pseudoreplicates per search 
(Stamatakis 2014; Stamatakis and Aberer 2013). AutoMRE was used to determine bootstrapping 
significance and ascertainment bias correction was implemented to account for the absence of 
invariant sites. For regular searches, RAxML was used to generate a starting tree using 
maximum parsimony from a random number seed, and ExaML for the search. For bootstrapping, 
160 computer cores were used per run of RAxML. Phylogenetic tree was rerooted to the wild-
canid clade (Golden Jackal) and monophyletic groups were color coded to indicate unique 
bipartitions.  
 
Principal Component Analysis 
DNA samples from 10 Siberian Huskies and 10 Alaskan Malamutes were genotyped 
using the Illumina CanineHD BeadChip following standard protocols (Illumina, Inc., San Diego 
CA). Genotypes from 10 Greenland Sledge Dogs were obtained from previously published data 
(Vaysse et al. 2011). A total of 135,833 SNPs were retained after comparison to the CTVT tumor 
sequence. All three data sources were combined and analyzed using EIGENSTRAT (Price et al. 
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2006). Significance of each PC was evaluated using Tracy-Widom statistics (Patterson et al. 
2006). 
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Data Access 
Sequencing data for each canid and CTVT genome have been submitted to the NCBI 
Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/sra) under accession numbers 
PRJEB7734-PRJEB7736, and PRJNA288568. The genotype data for 10 Alaskan malamutes and 
10 Siberian huskies have been submitted to the NCBI Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE70454. 
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Figure Legends 
Fig. 1. Founder-inherited versus somatic variation in CTVT. (A) Fraction of SNVs from 186 
sequenced canids found in canine dbSNP (mean 32.65%). Sequenced canids included the two 
host dogs, 64 dogs representing 40 modern breeds, 27 dogs representing 12 ancient breeds, 86 
outbred canids spanning four continents, and nine wild canids. (B-D) Fraction of SNVs, indels, 
and SVs found in a single canid that are present in at least one other canid in the panel (means of 
99.55%, 99.57%, and 95.63%, respectively). (E) High quality variants found in both CTVT 
tumors were compared against our Variant and Systematic Error Catalog (VSEC), which was 
generated from 186 canid whole genome sequences. Consensus CTVT variants present in the 
VSEC catalog were presumed to be alleles inherited by the founder canid. Novel variants were 
treated as somatic mutations, some of which are crucial to clonal transmissibility. Dog images 
from the American Kennel Club (http://www.akc.org). 
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Fig. 2. Candidate somatic mutations are highly enriched for true somatic mutations. (A-C) The 
transition-transversion ratio, nonsynonymous-synonymous ratio, and 4-way PhastCons score at 
missense substitution sites for CTVT somatic variants were statistically significant outliers (2-
sided Grubb’s test, critical value of Z for 188 observations = 3.59) compared to the both the 
canid WGS panel, as well as the CTVT founder’s inherited alleles. (D-F) Substitution profiles in 
their trinucleotide sequence context for germline variation averaged across the 186 canids (D), 
the CTVT founder’s putative inherited alleles (E), and the candidate CTVT somatic mutations 
(F). Germline variants have more C>T and T>C variants than other substitutions, but no 
dramatic overrepresentation of surrounding sequence contexts. In contrast, the CTVT candidate 
somatic mutations are enriched for C>T transitions, especially TCC>TTC (15.9%) and 
CCC>CTC (6.0%). Notably, the enrichment of T>C substitutions is also absent from the CTVT 
candidate somatic mutations. For all three plots, the base substitutions are indicated by color and 
displayed relative to the reference pyrimidine base (i.e., C>A and G>T transversions are shown 
together). Each bar conveys the fraction of variants for which the indicated substitution occurs in 
the context of the adjacent bases in the reference sequence. For example, the leftmost bar 
represents the percentage of mutations that are ACA>AAA transversions. 
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Fig. 3. Somatic mutations shared by both CTVT tumors lend insight into the biology of clonal 
transmissibility. (A) Somatic mutations impact all aspects of pathways involved in 
immunosurveillance. (B) 728 chromosome-to-chromosome translocations were shared by both 
tumors. (C) Recent LOH events are characterized by complete homozygosity of both alleles 
inherited by the CTVT founder and somatic SNVs, as in this example on Chromosome 6. (D) 
Older LOH events have elevated inherited SNV homozygosity, but low somatic mutation 
homozygosity, since SNVs that predate the LOH event are homozygous, but their relative 
contribution has been diminished by subsequent heterozygous mutations, as observed on 
Chromosome 7. Plots for all chromosomes can be found in Fig. S2.  
 
 
 
 
 
 
 
 
 
 
 
 
 Cold Spring Harbor Laboratory Press on August 13, 2015 - Published by genome.cshlp.orgDownloaded from 
  28
 
Fig. 4. Dissection of the rebuilt founder canid’s genome. (A) Maximum Likelihood phylogeny of 
canine variation catalog using putative founder-inherited variant positions with clades colored by 
monophyly. Position of the CTVT germline genomes indicate that the founder was a post-wolf 
canine with closest similarity to a contemporary Arctic spitz breed. Observed acceleration on the 
CTVT branch is due to the use of all positions determined to vary from reference in the CTVT 
germline, therefore ensuring the proportion of these variant characters exceeds all other 
genomes. For the unrooted maximum likelihood tree with bootstrap support, see Fig. S3. (B) We 
used 135,833 SNPs from the Illumina HD chip and genotypes extracted from the tumor WGS to 
perform principal components analysis on the CTVT tumors and dogs from three Arctic spitz 
breeds. The CTVT founder was likely most genetically similar to the modern Alaskan malamute. 
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Tables 
Table 1. Panel of 186 canid genome sequences and functional annotations efficiently highlight 
high-priority somatic mutations. 
 
  
Candidate Somatic CTVT Variants 
  
Single Nucleotide 
Substitutions Indels 
Structural 
Variants 
HQ Variants in Both Tumors 3,728,916 1,435,051 8,903  
   Not In VSEC Catalog 910,376 113,026 7,338  
      Damaging Missense / In-Frame 5,019 285 N/A  
      Truncating / Disrupting 586 723 2,920 
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Supplementary Materials 
Figures S1-S5 
Tables S1-S9 
Databases S1-3 
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